“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, October 23, 2015:Pharma major Lupin today announced the appointment of Fabrice Egros as
President, Asia Pacific and Japan. He will be based in Tokyo, Japan. Fabrice has over 25 years of experience
within the global pharmaceutical industry, having worked in leadership roles encompassing P&L management
for new markets, mergers & acquisitions, marketing & commercial, global strategy and business development as
well as global clinical development, regulatory and manufacturing. He will be responsible for Lupin's growth and
development across key markets such as Japan, Australia, the Philippines, South East Asia and new markets in
the rest of the ASEAN region. Prior to joining Lupin, Fabrice was with NovaMedica where he was the Deputy
CEO/ COO and instrumental in setting up an integrated new pharmaceutical business. Before NovaMedica, he
has worked with global majors such as UCB, Sanofi and Parke Davis in various global and regional capacities.
Fabrice holds a Degree in Pharmacy, a MS in clinical pharmacology and a Doctorate in Pharmaceutical Sciences
from the University of Paris (School of Medicine and Pharmacy) as well as a MBA from Schiller University. He has
also completed Advanced Management Program from Harvard University.
Commenting on the appointment, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, "We are delighted
to have Fabrice join the Lupin family. His deep knowledge of the Asia-Pacific markets will be invaluable as we
consolidate and grow our business in the region. This region is the third largest revenue contributor for us
globally and I believe that Fabrice's experience will help Lupin achieve its growth plans for the Asia Pacific region,
and help us scale the business to new heights."
About Lupin Limited
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and
developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The
Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and
NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions,IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th – IMS Health).
For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were 125,997 million (USD 2.06 billion) and 24,032 million (USD 393 million) respectively. Please visit http://www.lupin.com for more information.
You could also follow us on Twitter – www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.
For further information or queries please contact -
Head – Corporate Communications
Ph: +91 98 20 338 555
Head – M & A and Investor Relations
Ph: +91 98 20 023 511
Safe Harbor Statement